The expression of proenkephalin and prodynorphin genes and the induction of c-fos gene by dopaminergic drugs are not altered in the striatum of MPTP-treated mice

1995 ◽  
Vol 9 (2-3) ◽  
pp. 151-164 ◽  
Author(s):  
B. Ziolkowska ◽  
G. Horn ◽  
A. Kupsch ◽  
V. Höllt
Keyword(s):  
Dopaminergic Drugs

Schizophrenia, Parkinson’s disease, and attention deficit hyperactivity disorder

2018 ◽  
Author(s):  
Richard J. Beninger
Keyword(s):  
Parkinson’S Disease ◽  
Attention Deficit Hyperactivity Disorder ◽  
Parkinson's Disease ◽  
Attention Deficit ◽  
Antipsychotic Treatment ◽  
Incentive Learning ◽  
Dopaminergic Drugs ◽  
Dopaminergic Neurotransmission ◽  
Hyperactivity Disorder ◽  
Incentive Value

Schizophrenia, Parkinson’s disease, and attention deficit hyperactivity disorder (ADHD) discusses how hyperactive dopaminergic neurotransmission appears to underlie schizophrenia’s positive symptoms, loss of dopaminergic neurons in adulthood leads to Parkinson’s disease, and dopamine neuron hypofunction in childhood and adolescence may underlie ADHD. Positive schizophrenia symptoms may arise from excessive incentive learning that is gradually lost with antipsychotic treatment. Declarative learning and memory may contribute to delusions based on excessive incentive learning. Loss of responsiveness to environmental stimuli in Parkinson’s may result from a decrease of their conditioned incentive value and inverse incentive learning. Conditioned incentive stimuli not encountered while in a state of decreased dopaminergic neurotransmission may retain their incentive value, producing apparent kinesia paradoxa. Dopamine hypofunction in juveniles does not lead to hypokinesia but may result in loss of incentive learning that focuses attention. Pro-dopaminergic drugs have a calming effect in ADHD, presumably because they reinstate normal incentive learning.

The electrophysiological actions of dopamine and dopaminergic drugs on neurons of the substantia nigra pars compacta and ventral tegmental area

Life Sciences ◽  
1992 ◽  
Vol 51 (10) ◽  
pp. 711-718 ◽  
Author(s):  
Nicola B. Mercuri ◽  
Paolo Calabresi ◽  
Giorgio Bernardi
Keyword(s):  
Substantia Nigra ◽  
Ventral Tegmental Area ◽  
Substantia Nigra Pars Compacta ◽  
Dopaminergic Drugs ◽  
Ventral Tegmental

scholarly journals Actions of dopamine and dopaminergic drugs on cloned serotonin receptors expressed in Xenopus oocytes.

1992 ◽  
Vol 89 (10) ◽  
pp. 4708-4712 ◽  
Author(s):  
R. M. Woodward ◽  
M. M. Panicker ◽  
R. Miledi
Keyword(s):  
Serotonin Receptors ◽  
Xenopus Oocytes ◽  
Dopaminergic Drugs

scholarly journals Monoamine Oxidase and Cerebral Uptake of Dopaminergic Drugs

1974 ◽  
Vol 71 (7) ◽  
pp. 2715-2719 ◽  
Author(s):  
G. C. Cotzias ◽  
L. C. Tang ◽  
J. Z. Ginos
Keyword(s):  
Monoamine Oxidase ◽  
Dopaminergic Drugs

Non-Dopaminergic Drugs for Motor Symptoms

2012 ◽  
pp. 881-892
Author(s):  
Pierre Burkhard ◽  
Francois Vingerhoets
Keyword(s):  
Motor Symptoms ◽  
Dopaminergic Drugs

scholarly journals Pramipexole and tolcapone alleviate thermal and mechanical nociception in naive rats.

Folia Medica ◽  
2021 ◽  
Vol 63 (3) ◽  
pp. 377-384
Author(s):  
Anita Mihaylova ◽  
Ilia Kostadinov ◽  
Nina Doncheva ◽  
Delian Delev ◽  
Hristina Zlatanova
Keyword(s):  
Neurodegenerative Disorder ◽  
Antinociceptive Effect ◽  
Positive Control ◽  
Motor Symptoms ◽  
Dopaminergic Drugs ◽  
Thermal Nociception ◽  
Dopaminergic Neurotransmission ◽  
Latent Time ◽  
Male Wistar Rats ◽  
Non Motor Symptoms

Introduction: Parkinson&rsquo;s disease (PD) is &#1072; neurodegenerative disorder characterized mainly by its motor symptoms. The non-motor symptoms including pain are increasingly recognized in the last few decades. Existing evidence suggests that the dopaminergic neurotransmission has an essential role in pain control. Aim: The aim of the present study was to investigate the antinociceptive effect of dopaminergic drugs pramipexole and tolcapone against chemical and thermal stimuli in naive rats. Materials and methods: Male Wistar rats divided into 8 groups (n=8): saline; diclofenac 25 mg/kg body weight (bw) (positive control); pramipexole 0.5; 1 and 3 mg/kg bw; tolacapone 5; 15 and 30 mg/kg bw. Paw pressure and plantar tests were performed. Paw withdrawal pressure and latent time were measured. Statistical analysis was done by SPSS 19. Results: In the paw pressure test, pramipexole, in a dose of 1 and 3 mg/kg bw and tolcapone in a dose of 30 mg/kg bw, increased significantly the latency at 1, 2, and 3 hours compared to saline (p<0.05). In the plantar test, only the highest dose of pramipexole reached significance at 3 hours compared to the control rats (p<0.05). In contrast to pramipexole the three experimental groups with tolcapone markedly increased the latent time at 1 and 3 hours compared to saline (p<0.05). Conclusions: Pramipexole and tolcapone reduce mechanical and thermal nociception in na&iuml;ve rats by enhancing dopaminergic neurotransmission at both spinal and supraspinal levels. In addition, tolcapone stimulates noradrenergic mediation which may contribute to its antinociceptive effect.

scholarly journals Role of the Dopaminergic System in the Striatum and Its Association With Functional Recovery or Rehabilitation After Brain Injury

2021 ◽  
Vol 15 ◽  
Author(s):  
Antonio Verduzco-Mendoza ◽  
Paul Carrillo-Mora ◽  
Alberto Avila-Luna ◽  
Arturo Gálvez-Rosas ◽  
Adriana Olmos-Hernández ◽  
...  
Keyword(s):  
Brain Injury ◽  
Functional Recovery ◽  
Dopaminergic System ◽  
Brain Structures ◽  
Receptor Activation ◽  
Important Goal ◽  
Dopaminergic Drugs ◽  
Beneficial Effects ◽  
Severe Tbi

Disabilities are estimated to occur in approximately 2% of survivors of traumatic brain injury (TBI) worldwide, and disability may persist even decades after brain injury. Facilitation or modulation of functional recovery is an important goal of rehabilitation in all patients who survive severe TBI. However, this recovery tends to vary among patients because it is affected by the biological and physical characteristics of the patients; the types, doses, and application regimens of the drugs used; and clinical indications. In clinical practice, diverse dopaminergic drugs with various dosing and application procedures are used for TBI. Previous studies have shown that dopamine (DA) neurotransmission is disrupted following moderate to severe TBI and have reported beneficial effects of drugs that affect the dopaminergic system. However, the mechanisms of action of dopaminergic drugs have not been completely clarified, partly because dopaminergic receptor activation can lead to restoration of the pathway of the corticobasal ganglia after injury in brain structures with high densities of these receptors. This review aims to provide an overview of the functionality of the dopaminergic system in the striatum and its roles in functional recovery or rehabilitation after TBI.

Effects of dopaminergic drugs on the mast cell degranulation and nitric oxide generation in RAW 264.7 cells

2004 ◽  
Vol 27 (1) ◽  
pp. 94-98 ◽  
Author(s):  
II-Woong Seol ◽  
Na Youn Kuo ◽  
Kyeong Man Kim
Keyword(s):  
Nitric Oxide ◽  
Mast Cell ◽  
Mast Cell Degranulation ◽  
Raw 264.7 Cells ◽  
Raw 264.7 ◽  
Dopaminergic Drugs

Alterations in striatal neurotrophic activity induced by dopaminergic drugs

1993 ◽  
Vol 46 (1) ◽  
pp. 195-204 ◽  
Author(s):  
Paul M. Carvey ◽  
Louis R. Ptak ◽  
Donghui Lin ◽  
Erwin S. Lo ◽  
Colleen M. Buhrfiend ◽  
...  
Keyword(s):  
Dopaminergic Drugs ◽  
Neurotrophic Activity
Sign in / Sign up

Export Citation Format

Share Document